Kodiak Sciences to Present at Upcoming Conferences
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on retinal diseases, will present at two upcoming virtual investor conferences. The first is the Truist Securities 2021 Life Sciences Summit on May 4 at 8:20 a.m. PT, and the second is the UBS Global Healthcare Virtual Conference on May 25 at 12:00 p.m. PT. A live webcast will be available on Kodiak's website and can be replayed for a limited time. Kodiak is known for its ABC Platform™ and lead product candidate KSI-301, targeting major retinal vascular diseases.
- None.
- None.
PALO ALTO, Calif., April 21, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that management will present at the following upcoming virtual investor conferences:
- Truist Securities 2021 Life Sciences Summit on Tuesday, May 4 at 8:20 a.m. Pacific Time (11:20 a.m. Eastern Time)
- UBS Global Healthcare Virtual Conference on Tuesday, May 25 at 12:00 p.m. Pacific Time (3:00 p.m. Eastern Time)
A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
View original content:http://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-upcoming-conferences-301274352.html
SOURCE Kodiak Sciences Inc.
FAQ
When is Kodiak Sciences presenting at the Truist Securities 2021 Life Sciences Summit?
What date will Kodiak Sciences present at the UBS Global Healthcare Virtual Conference?
Where can I watch the Kodiak Sciences conference presentations?
What is Kodiak Sciences' lead product candidate?
What technology does Kodiak Sciences use for its therapeutics?
